Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies

2021-10-06T12:25:59+01:00

Tofacitinib should not be used in patients older than 65 years of age, people who are current or past smokers, or individuals with other cardiovascular (such as diabetes or coronary artery disease) or malignancy risk factors unless there are no suitable treatment alternatives.